Clinical Trials

Targeted Therapy

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

LEARN MORE

Beyond First Line Therapy

This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.

LEARN MORE

Beyond First Line Therapy

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

LEARN MORE

Beyond First Line Therapy

ICP-CL-00303

LEARN MORE

Beyond First Line Therapy

Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC)

LEARN MORE

Immunotherapy

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

LEARN MORE

Beyond First Line Therapy

CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210)

LEARN MORE

Beyond First Line Therapy

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

LEARN MORE

Other Novel Therapies

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

LEARN MORE

First Line Therapy

A Phase II study of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of Floxuridine and Dexamethasone given concurrently with systemic mFOLFIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma (HELIX-ICC)

LEARN MORE

First Line Therapy

TAS-120-301(FOENIX-CCA3)

LEARN MORE

First Line Therapy

Gemcitabine and Cisplatin With or Without CPI-613 (Devimistat)as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

LEARN MORE